The market has been down on Halozyme Therapeutics, Inc. (HALO) stock recently. HALO gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.
Halozyme Therapeutics, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HALO!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With HALO Stock Today?
Halozyme Therapeutics, Inc. (HALO) stock is up 3.28% while the S&P 500 is lower by -0.65% as of 1:04 PM on Thursday, Sep 30. HALO is higher by $1.30 from the previous closing price of $39.65 on volume of 252,239 shares. Over the past year the S&P 500 is higher by 29.85% while HALO is higher by 54.47%. HALO earned $1.56 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.32.
To see InvestorsObserver's Sentiment Score for Halozyme Therapeutics, Inc. click here.
More About Halozyme Therapeutics, Inc.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.